Prognostic Significance of Mesenchymal-Epithelial Transition in Triple-Negative Breast Cancers

MET is an adverse prognostic marker for TNBCs. The results strengthen the rationale for targeted therapy of TNBCs using MET inhibitors in future clinical trials.